Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 18.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,817,446 shares of the biotechnology company’s stock after purchasing an additional 1,657,267 shares during the quarter. Vanguard Group Inc. owned approximately 11.07% of Sarepta Therapeutics worth $208,452,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State of Michigan Retirement System grew its holdings in shares of Sarepta Therapeutics by 3.1% during the second quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock worth $404,000 after buying an additional 700 shares in the last quarter. Arizona State Retirement System boosted its position in Sarepta Therapeutics by 2.8% during the third quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company’s stock worth $504,000 after acquiring an additional 717 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in Sarepta Therapeutics by 3.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock valued at $396,000 after acquiring an additional 744 shares in the last quarter. New York Life Investment Management LLC raised its holdings in Sarepta Therapeutics by 10.0% in the 2nd quarter. New York Life Investment Management LLC now owns 10,623 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 966 shares during the last quarter. Finally, AlphaQuest LLC lifted its stake in Sarepta Therapeutics by 118.3% in the 3rd quarter. AlphaQuest LLC now owns 2,561 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,388 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Key Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue beat estimates in Q4 ($442.9M vs. ~$391M consensus), which partially offsets earnings weakness and suggests underlying commercial traction outside the challenged product. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Wells Fargo kept an “overweight” rating on SRPT, implying continued analyst conviction in the story despite lowering its price target to $38 (from $45), signaling potential upside from current levels. Wells Fargo Lowers Price Target
• Neutral Sentiment: Sarepta expanded non-market PR and community programs — opening applications for the Route 79 Duchenne scholarship — which supports brand and patient-community relations but is unlikely to move near-term valuation. Sarepta Announces Route 79 Scholarship
• Neutral Sentiment: Sarepta plans to present long-term and safety data at the upcoming MDA conference — data releases could be material but timing and contents are uncertain. Sarepta to Present Long-Term Data at MDA
• Negative Sentiment: Large Q4 EPS miss: reported EPS was far worse than consensus (reported loss −$3.58 vs. est. −$0.87), driven by a steep decline in ELEVIDYS sales and a wider net loss, increasing short-term revenue and margin uncertainty. Sarepta Q4 Earnings Report
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon his replacement), introducing leadership transition risk at a sensitive time for product recovery and strategy execution. Reuters: Sarepta CEO Ingram to Retire
• Negative Sentiment: Institutional selling: AXQ Capital materially trimmed its SRPT stake (large percentage reduction), which can add selling pressure and signal reduced conviction among some holders. AXQ Capital Lowers Position in Sarepta

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SRPT shares. Wedbush upped their price target on Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Robert W. Baird lowered their price target on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Guggenheim decreased their target price on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Finally, Wells Fargo & Company dropped their price target on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Hold” and an average target price of $33.56.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. This trade represents a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.60% of the stock is owned by company insiders.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $16.76 on Monday. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $108.48. The stock has a market capitalization of $1.76 billion, a PE ratio of -1.99, a PEG ratio of 0.27 and a beta of 0.42. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. The stock has a 50-day simple moving average of $20.43 and a 200-day simple moving average of $20.22.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) EPS for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The firm had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. During the same quarter last year, the firm earned $1.90 EPS. The company’s revenue was down 32.7% on a year-over-year basis. On average, analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.